NASDAQ:ZGNX - Zogenix Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $37.82 +0.60 (+1.61 %) (As of 05/21/2019 02:42 PM ET)Previous Close$37.22Today's Range$37.24 - $37.975052-Week Range$33.43 - $62.75Volume185,112 shsAverage Volume668,138 shsMarket Capitalization$1.61 billionP/E RatioN/ADividend YieldN/ABeta1.96 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of transformative central nervous system disorders in the United States. Its lead product candidate is the Fintepla/ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in Emeryville, California. Receive ZGNX News and Ratings via Email Sign-up to receive the latest news and ratings for ZGNX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:ZGNX Previous Symbol CUSIP98978L10 CIK1375151 Webwww.zogenix.com Phone510-550-8300Debt Debt-to-Equity Ratio0.02 Current Ratio9.12 Quick Ratio9.12Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$9.82 million Price / Sales163.47 Cash FlowN/A Price / Cash FlowN/A Book Value$11.71 per share Price / Book3.23Profitability EPS (Most Recent Fiscal Year)($3.23) Net Income$-123,910,000.00 Net MarginsN/A Return on Equity-26.77% Return on Assets-21.00%Miscellaneous Employees90 Outstanding Shares42,446,000Market Cap$1.61 billion Next Earnings Date8/5/2019 (Estimated) OptionableOptionable Zogenix (NASDAQ:ZGNX) Frequently Asked Questions What is Zogenix's stock symbol? Zogenix trades on the NASDAQ under the ticker symbol "ZGNX." How were Zogenix's earnings last quarter? Zogenix, Inc. (NASDAQ:ZGNX) posted its earnings results on Wednesday, May, 8th. The company reported ($0.83) earnings per share for the quarter, topping analysts' consensus estimates of ($0.85) by $0.02. View Zogenix's Earnings History. When is Zogenix's next earnings date? Zogenix is scheduled to release their next quarterly earnings announcement on Monday, August 5th 2019. View Earnings Estimates for Zogenix. What price target have analysts set for ZGNX? 12 brokers have issued 1-year price objectives for Zogenix's shares. Their forecasts range from $40.00 to $116.00. On average, they anticipate Zogenix's stock price to reach $62.5455 in the next twelve months. This suggests a possible upside of 65.4% from the stock's current price. View Analyst Price Targets for Zogenix. What is the consensus analysts' recommendation for Zogenix? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zogenix. What are Wall Street analysts saying about Zogenix stock? Here are some recent quotes from research analysts about Zogenix stock: 1. Mizuho analysts commented, "We gave consideration to (70% PoS). DCF: We assumed a 13% discount rate and a terminal value of 4.5x our estimated 2028 FCF of $861 mil. EV/Sales: we apply a 8x multiple to discounted 2025 sales of $352 mil. the U.S. market, we assume 4Q19 launch and peak market share of 75% (among new therapies) in 2028, equivalent to $526mn in peak sales; for EU and Japan, we assume late 2021 and late 2022 launches. For LGS, we project peak market penetration of 14% in 2028 in the U.S and PoS adjusted sales of $463mn." (3/19/2019) 2. According to Zacks Investment Research, "Zogenix is a specialty biopharmaceutical company focused on developing therapies for patients with rare central nervous system conditions that have limited or no treatment options. The company is currently pursuing two therapies targeting the Dravet Syndrome and the Lennox-Gastaut Syndrome. " (2/23/2019) Has Zogenix been receiving favorable news coverage? Media stories about ZGNX stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Zogenix earned a coverage optimism score of 1.3 on InfoTrie's scale. They also gave news articles about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the near term. Are investors shorting Zogenix? Zogenix saw a increase in short interest in the month of April. As of April 15th, there was short interest totalling 8,618,455 shares, an increase of 18.2% from the March 29th total of 7,290,204 shares. Based on an average trading volume of 1,953,594 shares, the short-interest ratio is currently 4.4 days. Approximately 21.5% of the company's shares are sold short. View Zogenix's Current Options Chain. Who are some of Zogenix's key competitors? Some companies that are related to Zogenix include GALAPAGOS NV/S (GLPG), Amarin (AMRN), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Ascendis Pharma A/S (ASND), Array Biopharma (ARRY), Horizon Therapeutics (HZNP), TESARO (TSRO), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Alkermes (ALKS), American Brivision (Holding) (ABVC), Evotec (EVTCY), Blueprint Medicines (BPMC) and HUTCHISON CHINA/S (HCM). What other stocks do shareholders of Zogenix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals PLC- (GWPH), Vanda Pharmaceuticals (VNDA), Gilead Sciences (GILD), QUALCOMM (QCOM), Canopy Growth (CGC), Southwest Airlines (LUV), Celgene (CELG), Novavax (NVAX), NVIDIA (NVDA) and AbbVie (ABBV). Who are Zogenix's key executives? Zogenix's management team includes the folowing people: Dr. Stephen J. Farr, Co-Founder, CEO, Pres & Director (Age 60)Mr. Michael P. Smith, Exec. VP, CFO, Treasurer & Sec. (Age 51)Dr. Bradley S. Galer, Exec. VP & Chief Medical Officer (Age 57)Dr. Gail M. Farfel, Exec. VP & Chief Devel. Officer (Age 55)Mr. Ashish M. Sagrolikar, Exec. VP & Chief Commercial Officer Who are Zogenix's major shareholders? Zogenix's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (11.09%), Perceptive Advisors LLC (9.12%), BlackRock Inc. (7.87%), Cadian Capital Management LP (3.14%), Eagle Asset Management Inc. (2.21%) and Marshall Wace LLP (1.33%). Company insiders that own Zogenix stock include Bradley S Galer, Cam L Garner, Erle T Mast, Gail M Farfel, Life Sciences Maste Perceptive, Renee P Tannenbaum, Roger Hawley and Stephen J Farr. View Institutional Ownership Trends for Zogenix. Which major investors are selling Zogenix stock? ZGNX stock was sold by a variety of institutional investors in the last quarter, including Cadian Capital Management LP, BlackRock Inc., Broadfin Capital LLC, Westfield Capital Management Co. LP, Voya Investment Management LLC, Morgan Stanley, Jefferies Group LLC and Apis Capital Advisors LLC. Company insiders that have sold Zogenix company stock in the last year include Cam L Garner, Erle T Mast, Gail M Farfel, Renee P Tannenbaum, Roger Hawley and Stephen J Farr. View Insider Buying and Selling for Zogenix. Which major investors are buying Zogenix stock? ZGNX stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace LLP, Perceptive Advisors LLC, Loomis Sayles & Co. L P, Teacher Retirement System of Texas, Dimensional Fund Advisors LP, Pictet Asset Management Ltd. and Geode Capital Management LLC. Company insiders that have bought Zogenix stock in the last two years include Bradley S Galer and Life Sciences Maste Perceptive. View Insider Buying and Selling for Zogenix. How do I buy shares of Zogenix? Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Zogenix's stock price today? One share of ZGNX stock can currently be purchased for approximately $37.82. How big of a company is Zogenix? Zogenix has a market capitalization of $1.61 billion and generates $9.82 million in revenue each year. The company earns $-123,910,000.00 in net income (profit) each year or ($3.23) on an earnings per share basis. Zogenix employs 90 workers across the globe. What is Zogenix's official website? The official website for Zogenix is http://www.zogenix.com. How can I contact Zogenix? Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected] MarketBeat Community Rating for Zogenix (NASDAQ ZGNX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 371 (Vote Outperform)Underperform Votes: 268 (Vote Underperform)Total Votes: 639MarketBeat's community ratings are surveys of what our community members think about Zogenix and other stocks. Vote "Outperform" if you believe ZGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZGNX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/21/2019 by MarketBeat.com StaffFeatured Article: Average Daily Trade Volume - What You Need to Know Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.